Canadian generics now reaching pharmacies Health Canada authorized the first generic semaglutide injection on April 28, 2026, calling it the first such authorization in the G7
It is better described as more active at MC1R, rather than fully selective, since most melanocortin peptides can act on multiple receptors
While we strive to keep our content current with the latest research and clinical guidelines, it is intended for general informational purposes only
doi: 10.1098/rsfs.2017.0030
In summary, as time progresses and systems improve, the number of ADE reports for semaglutide may increase, and its safety signal spectrum may continually evolve
While semaglutide can seem like a wonder drug, the medication can have side effects and risks and is a long-term commitment